Valuation : Genmab A/S

Market Cap 128B 19.88B 17.15B 16.13B 14.7B 27.64B 1,887B 27.79B 191B 74.23B 960B 74.65B 73.03B 3,183B P/E 2026 *
27.2x
P/E 2027 * 19.1x
Enterprise Value 147B 22.86B 19.72B 18.55B 16.9B 31.78B 2,169B 31.95B 219B 85.34B 1,104B 85.82B 83.96B 3,659B EV / Sales 2026 *
5.09x
EV / Sales 2027 * 4.13x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+1.18%
1 week-2.23%
Current month+1.18%
1 month+15.52%
3 months+30.99%
6 months+16.15%
Current year+5.92%
1 week 2,095
Extreme 2095
2,198
1 month 1,819.5
Extreme 1819.5
2,198
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%-2.23%+30.87%-19.04% 19.88B
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.12%-5.82%-1.68%+531.29% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
+0.42%-6.91%+275.58%+195.92% 11.69B
Average +0.05%-4.22%+68.18%+202.27% 27.48B
Weighted average by Cap. +0.16%-3.38%+51.17%+159.16%

Financials

2026 *2027 *
Net sales 28.97B 4.49B 3.88B 3.65B 3.32B 6.25B 426B 6.28B 43.1B 16.78B 217B 16.87B 16.5B 719B 33.74B 5.23B 4.51B 4.25B 3.87B 7.27B 497B 7.31B 50.2B 19.54B 253B 19.65B 19.22B 838B
Net income 4.93B 764M 659M 620M 565M 1.06B 72.54B 1.07B 7.33B 2.85B 36.9B 2.87B 2.81B 122B 7.17B 1.11B 959M 903M 822M 1.55B 106B 1.55B 10.67B 4.15B 53.7B 4.18B 4.09B 178B
Net Debt 19.19B 2.98B 2.57B 2.42B 2.2B 4.14B 283B 4.16B 28.56B 11.12B 144B 11.18B 10.94B 477B 11.03B 1.71B 1.48B 1.39B 1.26B 2.38B 162B 2.39B 16.4B 6.38B 82.56B 6.42B 6.28B 274B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-09-01 DKK 2,147.00 +1.18% 94,381
26-08-31 DKK 2,122.00 -1.58% 239,287
26-08-28 DKK 2,156.00 -0.51% 80,778
26-08-27 DKK 2,167.00 +0.37% 71,248
26-08-26 DKK 2,159.00 -1.68% 100,182
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,147.00DKK
Average target price
2,427.12DKK
Spread / Average Target
+13.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock